Stock Analysis, Dividends, Split History
CTL / CenturyLink, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.
|Market Cap ($M)||24,562.00|
|Enterprise Value ($M)||61,177.00|
|Book Value ($M)||22,989.00|
|Book Value / Share||21.28|
|Price / Book||1.07|
|NCAV / Share||n/a|
|Price / NCAV||n/a|
|Common Shares Outstanding||1,069,861,684|
|Preferred Stock Shares Outstanding||7,000|
|Common Stock Shares Outstanding||1,069,169,000|
|Altman Z Score||N/A|
|Beneish M Score||N/A|
|Management Effectiveness (mra)|
|Return on Invested Capital (ROIC)||0.02|
|Return on Assets (ROA)||0.03|
|Return on Equity (ROE)||0.10|
|Identifiers and Descriptors|
|Central Index Key (CIK)||18926|
|99AAYRM9X 156700906 156700956 156686107|
|SIC 4813 - Telephone Communications, Except Radiotelephone|
Stock splits are used by CenturyLink, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.
16h - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
16h - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
18h - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Related News Stories
For investors seeking protection, dividend stocks offer significant advantages. Principally, they offer passive income that can either boost overall returns or help mitigate market volatility. Usually though, dividend-paying companies tend to be boring affairs. (8-0)
When it comes to dividend stocks, none are as generally well-regarded as “dividend aristocrats.” A true dividend aristocrat” is more than just another name among other high-yield stocks. (18-0)
SAN FRANCISCO (Reuters) - Alphabet Inc, Facebook Inc, Netflix Inc and others will be in focus on Sept. 24 when they are moved out of the tech and consumer discretionary sectors into a deepened pool of communication and media stocks. (42-0)
CenturyLink, Inc. (CTL - Free Report) recently introduced a suite of fiber-based broadcast services that enables safe, secure and seamless connectivity to cloud-based media services and workflows. Dubbed the Vyvx Cloud Connect, the new network service facilitates broadcasters as well as studio and stadium venues across the country to easily upload live and linear video into and out of the cloud. The Vyvx Cloud Connect service provides easy connectivity to Amazon Web Services, the on-demand cloud-computing platform of Amazon. (36-0)
This article series provides a monthly dashboard of industries in each sector of the GICS classification. It compares valuation and quality factors relative to their historical averages in each industry. (22-0)
as of ET